ZYUS:CA:TSV-ZYUS Life Sciences Corporation (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.8

Change

0.00 (0.00)%

Market Cap

USD 0.06B

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada and internationally. The company offers cannabinoid oils, softgel capsules, and topical creams. ZYUS Life Sciences Corporation was founded in 2018 and is based in Saskatoon, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-16 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

N/A

USD 0.13B
LOVE:CA Cannara Biotech Inc

N/A

USD 0.07B
SBBC:CA Simply Better Brands Corp

N/A

USD 0.06B
LSL:CA LSL Pharma Group Inc.

N/A

USD 0.05B
HASH:CA Simply Solventless Concentrate..

N/A

USD 0.05B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.03B
ROMJ:CA Rubicon Organics Inc

N/A

USD 0.02B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.02B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B
VM:CA Voyageur Pharmaceuticals Ltd

N/A

USD 9.76M

ETFs Containing ZYUS:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.11% 61% D- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.11% 61% D- 57% F
Trailing 12 Months  
Capital Gain -5.88% 61% D- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.88% 61% D- 57% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.51% 53% F 46% F
Dividend Return -3.51% 53% F 46% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.94% 100% F 99% N/A
Risk Adjusted Return -44.28% 26% F 26% F
Market Capitalization 0.06B 90% A- 86% B+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector